Successful treatment using apatinib with or without docetaxel in heavily pretreated advanced non-squamous non-small cell lung cancer: A case report and literature review

Figures & data

Figure 1. Flow chart of patient management.

Figure 2. Response to apatinib monotherapy and combination treatment. A. Chest computed tomography (CT) scans before and after apatinib treatment. B. Chest CT scans before and after apatinib plus docetaxel combination treatment. Note, red arrows indicate the tumor.

Table 1. Clinical trials of antiangiogenic agents plus chemotherapy in advanced NSCLC approved by the FDA or EMA.

Authors, year	Clinical trials	Antiangiogenic agents	Chemotherapy	Approved lines of therapy	OS benefit compared to control
Alan Sandler et al, 2007^18	ECOG 4599 (phase III)	Bevacizumab	Paclitaxel-Carboplatin	First-line by FDA	2.0 months
Martin Reck et al, 2014^19	LUME-Lung 1 (phase III)	Nintedanib	Docetaxel	Second-line by EMA	2.3 months
Edward B Garon et al, 2014^20	REVEL (phase III)	Ramucirumab	Docetaxel	Second-line by FDA	1.4 months

Note: NSCLC, non-small cell lung cancer; FDA, Food and Drug Administration; EMA, European Medicines Agency.

Sandler A GR, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel–carboplatin alone or with Bevacizumab for non–small-cell lung cancer. New England J Med. 2007; 356:318. doi:10.1056/NEJMx070002.

 Web of Science ®Google Scholar

Reck M, Kaiser R, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M, von Pawel J, Gottfried M, Bondarenko I, Liao M, et al Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014;15:143-55. doi:10.1016/s1470-2045(13)70586-2.

 PubMed Web of Science ®Google Scholar

Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, Park K, Gorbunova V, Kowalyszyn RD, Pikiel J, et al Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet (London, England). 2014;384:665-73. doi:10.1016/s0140-6736(14)60845-x.

 PubMed Web of Science ®Google Scholar